Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Stop-codon read-through for patients affected by a lysosomal storage disorder|
|Citation:||Trends in Molecular Medicine, 2006; 12(8):367-373|
|Publisher:||Elsevier Sci Ltd|
|Abstract:||Lysosomal storage disorders are a group of inherited diseases that can result in severe and progressive pathology due to a specific lysosomal dysfunction. Current treatment strategies include bone-marrow transplantation, substrate reduction, chemical-chaperone and enzyme-replacement therapy. However, each of these treatments has its limitations. Enhanced stop-codon read-through is a potential alternative or adjunct therapeutic strategy for treating lysosomal-storage-disorder patients. Premature stop-codon mutations have been identified in a large cohort of patients with a lysosomal storage disorder, making stop-codon read-through a possible treatment for this disease. In lysosomal-storage-disorder cells (mucopolysaccharidosis type I, alpha-L-iduronidase deficient), preclinical studies have shown that gentamicin induced the read-through of premature stop codons, resulting in enzyme activity that reduced substrate storage.|
|Keywords:||Humans; Lysosomal Storage Diseases; Gentamicins; Codon, Terminator; Codon, Nonsense; Gene Expression Regulation; Models, Biological|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.